BioCryst Pharmaceuticals | 应收帐款人



金融业
股票价格
USD
资产
USD 446.42M
现金及等价物
USD 84.08M
销售成本
USD 12.27M
流动资产
USD 355.68M
流动负债
USD 190.24M
债务
USD 828.6M
股息收益率
0
EBIT
USD -4.51M
EBITDA
USD -20.3M
员工
536
EPS每股收益
USD -0.13
股本和储备
USD -387.89M
销售毛利
USD -88.88M
债务利息支出
USD 24.45M
利息收入
USD -0.13
贷款资金
USD 194.37M
市值
USD 1.3B
净收入
USD -88.88M
营业费用
USD -387.89M
营业利润
USD -2.54M
普通股股本
USD 1.9M
PE价格收益
1.08K
税前利润
USD -86.95M
销售收入
USD -86.95M
销售和管理费用
USD 80.47M
股票
USD 5.23M
贸易债权人
USD 5.57M
应收帐款人
USD 79.07M


应收帐款人 更改 日
Alnylam Pharmaceuticals USD 964.77M 397.66M 2025-09
BioCryst Pharmaceuticals USD 79.07M 6.61M 2024-12
Chugai Pharma JPY 443.11B 89.26B 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 5.1B 314M 2025-09
GlaxoSmithKline GBP 7.76B 545M 2025-12
Glaxosmithkline GBP 11.16B 3.46B 2025-09
Incyte USD 1.02B 128.52M 2025-12
Ionis Pharmaceuticals USD 24.61M 27.97M 2025-09
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
Neurocrine Biosciences USD 728M 132.3M 2025-09
Novavax USD 94.96M 62.81M 2024-09
PTC Therapeutics USD 203.07M 6.94M 2025-09
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 395.74M 213.86M 2025-09
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 1.95B 52.9M 2025-09


BioCryst Pharmaceuticals 应收帐款人 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.